IN2015DN03734A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN03734A IN2015DN03734A IN3734DEN2015A IN2015DN03734A IN 2015DN03734 A IN2015DN03734 A IN 2015DN03734A IN 3734DEN2015 A IN3734DEN2015 A IN 3734DEN2015A IN 2015DN03734 A IN2015DN03734 A IN 2015DN03734A
- Authority
- IN
- India
- Prior art keywords
- treatment
- compound
- pharmaceutically acceptable
- acceptable salt
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261710229P | 2012-10-05 | 2012-10-05 | |
| PCT/US2013/062964 WO2014055588A1 (en) | 2012-10-05 | 2013-10-02 | Treatment of mild and moderate alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03734A true IN2015DN03734A (es) | 2015-09-18 |
Family
ID=49354960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3734DEN2015 IN2015DN03734A (es) | 2012-10-05 | 2013-10-02 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2903606A1 (es) |
| JP (2) | JP6566868B2 (es) |
| KR (1) | KR20150064743A (es) |
| CN (2) | CN110292638A (es) |
| AU (2) | AU2013327450B2 (es) |
| BR (1) | BR112015007641A8 (es) |
| CA (1) | CA2886785C (es) |
| EA (1) | EA201590687A1 (es) |
| HK (1) | HK1207004A1 (es) |
| IL (1) | IL237730B (es) |
| IN (1) | IN2015DN03734A (es) |
| MX (1) | MX2015003732A (es) |
| NZ (2) | NZ705813A (es) |
| SG (2) | SG10201702648YA (es) |
| WO (1) | WO2014055588A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2019190823A1 (en) * | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| CA3110582A1 (en) | 2018-10-10 | 2020-04-16 | Vtv Therapeutics Llc | Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine |
| WO2020086388A1 (en) * | 2018-10-22 | 2020-04-30 | Vtv Therapeutics Llc | Glucokinase activator compositions for the treatment of cognitive impairment |
| JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
| CN114031687B (zh) * | 2021-11-12 | 2022-06-07 | 深圳市人民医院 | 靶向rage的纳米抗体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2324830A1 (en) * | 2002-03-05 | 2011-05-25 | TransTech Pharma Inc. | Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage |
| BRPI0410436A (pt) * | 2003-05-20 | 2006-05-30 | Transtech Pharma Inc | antagonistas de rage como agentes para amiloidose reversa e doenças associadas com a mesma |
| EP1707203A1 (en) * | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands |
| CN101663280A (zh) * | 2007-04-05 | 2010-03-03 | 转化技术制药公司 | [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ |
| CA2681864A1 (en) * | 2007-04-05 | 2008-10-16 | Transtech Pharma, Inc. | Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine |
| US20100254983A1 (en) * | 2007-06-07 | 2010-10-07 | Ann Marie Schmidt | Uses of rage antagonists for treating obesity and related diseases |
| US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
| WO2012061927A1 (en) * | 2010-11-08 | 2012-05-18 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
-
2013
- 2013-10-02 SG SG10201702648YA patent/SG10201702648YA/en unknown
- 2013-10-02 AU AU2013327450A patent/AU2013327450B2/en active Active
- 2013-10-02 BR BR112015007641A patent/BR112015007641A8/pt active Search and Examination
- 2013-10-02 KR KR1020157011366A patent/KR20150064743A/ko not_active Application Discontinuation
- 2013-10-02 EP EP13776676.2A patent/EP2903606A1/en not_active Withdrawn
- 2013-10-02 WO PCT/US2013/062964 patent/WO2014055588A1/en active Application Filing
- 2013-10-02 NZ NZ705813A patent/NZ705813A/en unknown
- 2013-10-02 JP JP2015535750A patent/JP6566868B2/ja active Active
- 2013-10-02 EA EA201590687A patent/EA201590687A1/ru unknown
- 2013-10-02 CA CA2886785A patent/CA2886785C/en active Active
- 2013-10-02 SG SG11201502210VA patent/SG11201502210VA/en unknown
- 2013-10-02 MX MX2015003732A patent/MX2015003732A/es active IP Right Grant
- 2013-10-02 NZ NZ739521A patent/NZ739521A/en unknown
- 2013-10-02 CN CN201910466681.3A patent/CN110292638A/zh active Pending
- 2013-10-02 IN IN3734DEN2015 patent/IN2015DN03734A/en unknown
- 2013-10-02 CN CN201380051206.0A patent/CN104703592A/zh active Pending
-
2015
- 2015-03-12 IL IL237730A patent/IL237730B/en active IP Right Grant
- 2015-08-11 HK HK15107776.8A patent/HK1207004A1/xx unknown
-
2018
- 2018-05-16 AU AU2018203434A patent/AU2018203434A1/en not_active Abandoned
-
2019
- 2019-05-23 JP JP2019096786A patent/JP6894940B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018203434A1 (en) | 2018-06-07 |
| SG10201702648YA (en) | 2017-04-27 |
| AU2013327450B2 (en) | 2018-07-12 |
| BR112015007641A2 (pt) | 2017-07-04 |
| CA2886785C (en) | 2022-06-07 |
| CA2886785A1 (en) | 2014-04-10 |
| JP2015535850A (ja) | 2015-12-17 |
| SG11201502210VA (en) | 2015-04-29 |
| JP6566868B2 (ja) | 2019-08-28 |
| WO2014055588A1 (en) | 2014-04-10 |
| JP2019163301A (ja) | 2019-09-26 |
| MX2015003732A (es) | 2015-09-23 |
| HK1207004A1 (en) | 2016-01-22 |
| CN110292638A (zh) | 2019-10-01 |
| IL237730B (en) | 2018-10-31 |
| BR112015007641A8 (pt) | 2018-04-03 |
| NZ705813A (en) | 2018-02-23 |
| AU2013327450A1 (en) | 2015-05-14 |
| EP2903606A1 (en) | 2015-08-12 |
| EA201590687A1 (ru) | 2015-09-30 |
| NZ739521A (en) | 2019-06-28 |
| CN104703592A (zh) | 2015-06-10 |
| JP6894940B2 (ja) | 2021-06-30 |
| KR20150064743A (ko) | 2015-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021007432A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| WO2015031564A3 (en) | Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors | |
| IN2015DN03734A (es) | ||
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| MX335941B (es) | Inhibidores sustituidos de n-[1-ciano-2- (fenil) etil]-2-azabiciclo[2.2.1] heptan-3-carboxamida de catepsina c. | |
| IN2014KN00948A (es) | ||
| NZ716487A (en) | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | |
| PH12015501661B1 (en) | Pyridone amides as modulators of sodium channels | |
| MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
| AU2013311573A8 (en) | Methods of treating Alzheimer's disease and pharmaceutical compositions thereof | |
| UA107865C2 (ru) | Гетероциклические карбоксамиды | |
| MD20140073A2 (en) | New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them | |
| IN2014DN10670A (es) | ||
| IN2015DN01119A (es) | ||
| TN2015000574A1 (en) | Compounds and compositions as inhibitors of mek | |
| MX2014004196A (es) | Citramida de rasagilina. | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| PH12015501398A1 (en) | New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity | |
| MX2015001917A (es) | Composiciones farmaceuticas de memantina. | |
| UA110128C2 (uk) | Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди |